Definium Therapeutics, Inc.

Definium Therapeutics to Participate at Upcoming Investor Conferences

Definium Therapeutics announced management will participate in four upcoming healthcare investor conferences in November and December 2026. Scheduled appearances include fireside chats at the Stifel 2026 Healthcare Conference, Jefferies Global Healthcare Conference in London, Evercore Healthcare Conference, and Piper Sandler 38th Annual Healthcare Conference, plus a psychedelics panel at Jefferies. Webcasts and replays will be available on the company's investor relations site for up to 90 days; no new business or clinical updates were disclosed.

•5d ago

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026

Definium Therapeutics will report third quarter 2026 financial results on November 9, 2026, hosting a webcast at 4:30 p.m. EST to discuss results and recent business highlights. The release is a routine scheduling notice with no financial figures or new business disclosures. A replay will be available on the company's investor relations site for at least 30 days.

•10d ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics granted inducement options to purchase an aggregate of 93,320 shares to six newly hired non-executive employees, with grant dates of October 26, 2026. The options carry an exercise price equal to the closing price on the grant date and vest over four years, and were approved under NASDAQ Rule 5635(c)(4) pursuant to the company's 2026 Inducement Plan. This is a routine equity-compensation disclosure with no earnings, pipeline, or capital-structure implications.

•13d ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics granted inducement options to purchase 45,940 common shares to two newly hired non-executive employees, with grant dates of October 13, 2026. The grants carry an exercise price equal to the grant-date closing price and vest over four years, approved under NASDAQ Rule 5635(c)(4) via the company's 2026 Inducement Plan. This is a routine administrative disclosure with no bearing on the company's clinical pipeline or financials.

•26d ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics granted inducement options to purchase an aggregate of 334,810 common shares to fifteen newly hired non-executive employees. The grants carry an exercise price equal to the closing price on the September 28, 2026 grant date and vest over four years, with 25% at the first anniversary. The awards were made under the company's 2026 Inducement Plan in accordance with NASDAQ Rule 5635(c)(4) and require no shareholder approval; the disclosure is routine boilerplate with no earnings or strategic implications.

•1mo ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics granted inducement stock options to purchase an aggregate of 56,650 common shares to three newly hired non-executive employees, with effective grant dates of September 14, 2026. The options have an exercise price equal to the closing share price on the grant date and vest over four years, with 25% vesting on the first anniversary and the remainder in monthly increments thereafter. The grants were made as a material inducement to employment under the company's 2026 Inducement Plan in accordance with NASDAQ Rule 5635(c)(4) -- a routine equity-compensation disclosure with no financial, clinical, or strategic impact.

•1mo ago

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

Definium Therapeutics will host a live webcast on September 14, 2026 at 8:00 a.m. EDT to discuss topline results from Panorama, its second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet in adults with generalized anxiety disorder. Panorama enrolled 245 participants across approximately 32 study centers, randomized 2:1:2 to single doses of DT120 ODT 100 µg, DT120 ODT 50 µg, or placebo. The primary endpoint is change from baseline in HAM-A total score at Week 12, with multiplicity-controlled secondary endpoints including CGI-S at Week 12 and early timepoints. No efficacy or safety data are included in this release; topline results will be disclosed at the webcast itself, setting up a near-term binary catalyst for DFTX's psychedelics-based GAD program.

•1mo ago

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

Definium Therapeutics will present topline Phase 3 data from its Emerge and Voyage trials of DT120 (lysergide) in major depressive disorder and generalized anxiety disorder at Psych Congress 2026, running September 15-19 in New Orleans. The congress program includes six posters plus an invited oral presentation in the Latest Discoveries & Emerging Trends in MDD session, covering Phase 3 topline results in both indications, the DT120 safety profile from Phase 1 and 2 studies, and number-needed-to-treat analyses. Chief Medical Officer Dan Karlin framed the presentations as reflecting DT120's broad potential across the two largest psychiatric disorders, alongside new epidemiological research on suicidal ideation timed to National Suicide Prevention Awareness Month. The release contains no actual efficacy or safety figures; the posters on September 17-18 are the first look at the topline data and represent the near-term catalyst for the stock.

•1mo ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics issued inducement grants to three newly hired non-executive employees, consisting of options to purchase an aggregate of 88,900 common shares. The options have an exercise price equal to the closing price on the grant date and will vest over a four-year period, with 25% vesting on the first anniversary. These grants were approved by the Compensation Committee on August 28, 2026, pursuant to NASDAQ Rule 5635(c)(4) and the company's 2026 Inducement Plan.

•2mo ago

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Definium Therapeutics announced that management will participate in three upcoming investor conferences beginning in September, kicking off with a Stifel-hosted webinar on September 1. The Stifel fireside chat will focus on the positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder and expectations for the upcoming Phase 3 Panorama study. Additional presentations include the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit and the 2026 Leerink Partners Biopharma Summit in late September.

•2mo ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics issued inducement grants to purchase an aggregate of 32,900 common shares to two newly hired non-executive employees. The options have an exercise price equal to the closing price on the grant date and vest over a four-year period, subject to continued employment. The grants were approved by the Compensation Committee on August 14, 2026, in accordance with NASDAQ Rule 5635(c)(4).

•2mo ago

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

This article is a paid advertisement and news commentary focusing on Helus Pharma (HELP), which has appointed Michael Halstead, former President of Intra-Cellular Therapies, as its new CEO. AtaiBeckley (ATAI) is mentioned solely within a section titled "The Companies Modernizing Psychiatric Treatment" to provide sector context, cited as an example of a multi-asset platform approach alongside peers like Definium Therapeutics and Compass Pathways. No specific business developments, financial results, or corporate actions regarding AtaiBeckley are disclosed in this release.

•3mo ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics granted inducement options to purchase an aggregate of 115,600 common shares to six newly hired non-executive employees. The options vest over a four-year period and were approved by the Compensation Committee on August 2, 2026, pursuant to NASDAQ Rule 5635(c)(4). Exercise prices were set equal to the closing price of the company's common shares on the grant date.

•3mo ago

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Definium Therapeutics announced it will report financial results for the second quarter ended June 30, 2026 on August 6, 2026. The company will host a webcast at 4:30 p.m. EDT to discuss the results and recent business highlights. A replay of the webcast will be accessible via the investor relations section of the Definium website for at least 30 days.

•3mo ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics granted inducement options to purchase an aggregate of 30,330 common shares to two newly hired non-executive employees. The options vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter, and were approved by the Compensation Committee under NASDAQ Rule 5635(c)(4). These grants were issued as a material inducement to employment pursuant to the company's 2026 Inducement Plan.

•3mo ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics granted inducement options to eight newly hired non-executive employees, covering an aggregate of 169,740 common shares. The options vest over a four-year period, with 25% vesting on the first anniversary and the remainder vesting in monthly installments thereafter. The grants were approved by the Compensation Committee in accordance with NASDAQ Rule 5635(c)(4) under the company's 2026 Inducement Plan.

•4mo ago

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

Definium Therapeutics priced an upsized public offering of 20,588,236 shares at $34.00 per share, generating expected gross proceeds of approximately $700 million. The company plans to use the net proceeds to fund research and development, preparation for potential commercialization of DT120 ODT, and general corporate purposes. J.P. Morgan, Jefferies, Leerink Partners, and BofA Securities are acting as joint lead bookrunners; the offering is expected to close on June 25, 2026.

•4mo ago

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Definium Therapeutics will host a webcast on June 22, 2026, at 8:00 a.m. EDT to discuss topline results from its Phase 3 Emerge study. The Emerge study evaluates a single 100 µg dose of DT120 ODT in 149 adults with major depressive disorder, using change in MADRS total score at Week 6 as the primary endpoint. This is one of two pivotal Phase 3 studies for DT120 in MDD; the second study, Ascend, includes a low-dose arm and is aligned with Emerge.

•4mo ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics issued 155,480 stock options to six newly hired non-executive employees as material inducements to employment. The grants were approved by the Compensation Committee on June 11, 2026, and issued on June 15, 2026, with exercise prices set at the closing price on the grant date. The options vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter, and were granted outside the company's existing equity incentive plans in compliance with NASDAQ Rule 5635(c)(4).

•4mo ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics issued 462,190 stock options to 13 newly hired non-executive employees as material inducements to employment. The grants were approved by the Compensation Committee in mid-May and late May 2026, with effective dates of May 18 and June 1, 2026. The options vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter, and were granted outside the company's standard equity incentive plans in compliance with NASDAQ Rule 5635(c)(4).

•5mo ago

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Definium Therapeutics announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The session is scheduled for June 3, 2026, at 3:10 p.m. EDT in New York. Audio webcasts and replays will be available on the company’s Investor Relations website for up to 90 days following the event.

•5mo ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics announced the issuance of inducement grants to five newly hired non-executive employees, consisting of options to purchase 255,340 common shares. The options will vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly increments over the following three years. The grants were approved by Definium's Compensation Committee and issued outside the company's equity incentive plans, in accordance with NASDAQ rules.

•5mo ago